最高の Biopharma ポッドキャスト (2024)

1
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments 22:38

1M ago22:38

22:38

Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital,…

1
Episode: 23 - An Industry Veteran’s Insight on Data Governance and Provenance 16:49

1M ago16:49

16:49

In this episode of Evaluating Biopharma, host Ben Locwin and Scott Endicott, executive leader of Healthcare Solutions Integration, talk about data governance and data provenance—why they matter and how the industry can achieve them. With 30 years of experience, Endicott has a deep understanding of training AI and ML models, particularly when patien…

1
Episode: 22 - Insider’s Advice for Starting, Growing, Exiting a Biotech 35:01

3M ago35:01

35:01

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Chris Major, founder and partner of BioProcess360 Partners, discuss the best ways to start a company to address technology gaps, why it is beneficial to collaborate with competitors (instead of going against each other), and the challenges encountered when planning to de-risk port…

1
Former Investor Who Chose Broadcasting Over Biotech ETFs 11:46

3M ago11:46

11:46

Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.RBC Capital Markets による

1
Biopharma EHS Podcast - Episode 29 Comparison of PDE Values (AI Generated) 11:57

3M ago11:57

11:57

This episode is a test use case where you can take a very technical scientific document and upload to a large language model to create a two-host podcast. The results were amazing.Dean Calhoun, CIH - Affygility Solutions による

1
Episode: 21 - How AI is Changing the Antibody R&D Game 31:35

4M ago31:35

31:35

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Tony Arulanandam, SVP and head of R&D at Cytovia Therapeutics, discuss how AI is impacting the antibody R&D field, how companies are using AI to generate better sequences and improve efficacy, and methods on approaching regulators and tackling regulatory challenges. Arulanandam al…

1
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery? 33:55

4M ago33:55

33:55

The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Cha…

1
Shots-on-Goal Licensing Company Aims for Breakthroughs 13:52

5M ago13:52

13:52

A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.RBC Capital Markets による

1
Episode: 20 - Optimal Talent Management in Biopharma with Mara Strandlund and Niamh Alix 19:38

5M ago19:38

19:38

In this month’s special episode of Evaluating Biopharma, host Ben Locwin interviews Mara Strandlund, chief people officer at National Resilience, and Niamh Alix, chief human resources officer at Prime Medicine, about the upcoming Talent in Biopharma Leadership workshop at the 2024 Bioprocessing Summit. Their conversation covers a wide variety of to…

1
Why Biopharma Needs to Tell Better Stories on Novel Drugs 15:31

6M ago15:31

15:31

Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.…

1
Venture capital velocity: What’s driving renewed momentum in biotech? 35:03

6M ago35:03

35:03

In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape. In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolvi…

1
Pharma Understands Phase One Data – But Does the Market? 25:30

6M ago25:30

25:30

Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.RBC Capital Markets による

1
Davern Capital sees GLP-1 Opportunities Beyond Obesity 9:39

6M ago9:39

9:39

Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.RBC Capital Markets による

1
Episode: 19 - The Critical Role of Starting Materials & Processes in Advanced Therapies 17:20

7M ago17:20

17:20

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Joaquim Vives, head of production of advanced therapies at Banc de Sang i Teixits, discuss cell and gene therapies and what sets them apart from other therapeutics in terms of their processes. Vives also talks about the top characteristics of good starting materials and particular…

1
Betting on Healthcare’s Future Hits – and Misses 14:47

7M ago14:47

14:47

As a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.RBC Capital Markets による

1
Innovation and an Aging Population Drive MedTech 16:01

7M ago16:01

16:01

The MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for fu…

1
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing 20:39

7M ago20:39

20:39

Personalized, targeted drugs and gene therapies are still at the forefront of medical innovation, as we discovered at RBC Capital Markets annual Doctor Days meetings. These insightful forums bring together key opinion leader clinicians and researchers from various therapeutic fields with institutional investors to discuss where opportunities lie, t…

1
Biotech with a Mission to Target Unmet Cancer Needs 13:37

7M ago13:37

13:37

IDEAYA’s drug development programs center around addressing unmet patient needs. Its founder tells Pathfinders in Biopharma why he believes there has never been more opportunity for breakthroughs in the fight against cancer.RBC Capital Markets による

1
Episode: 18 - Bispecific Antibodies: What Are They? How Do They Work? An Expert's Thoughts 23:56

7M ago23:56

23:56

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about bispecific antibodies. Dr. Schmidt goes into detail about current trends (from a CRO’s perspective) regarding the discovery and development phases of bispecific antibodies, why they are being made, and potential manufacturing issues. He…

1
The M&A Pool Set to Accelerate Biotech Innovation 13:51

9M ago13:51

13:51

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.…

1
How PIPEs finally unblocked biotech’s funding flows 17:36

9M ago17:36

17:36

The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been univ…

1
pcd pharma 3:08

9M ago3:08

3:08

Explore the intricate world of PCD (Propaganda Cum Distribution) Pharma with our comprehensive guide.Medroots Biopharma India による

1
Episode: 17 - Essential Program Management Considerations for Biopharma With Jamie Martin 22:56

10M ago22:56

22:56

In this episode of Evaluating Biopharma, host Ben Locwin and Jamie Martin, PMP, senior consultant at Black Diamond Networks, discuss the tips and tricks of successful program management. Martin shares his mental checklist of must-haves to ensure a successful start, techniques on what to do when things fall off-track, and the keys to continuous succ…

1
Episode: 16 - Brian Tham on Project Management and Continuous Improvement in Biopharma 21:21

10M ago21:21

21:21

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Brian Tham, principal consultant at Peregrine Bio, LLC, on how various projects are run in the pharmaceutical industry, how to improve the outcome and processes of projects, and how to continue improving processes and operational excellence. They also delve into the history of how…

1
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back 12:58

10M ago12:58

12:58

U.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three disruptive forces in the digital health space are speeding change – and adding up to a healthy outlook for HCIT. Sean Dodge, Healthcare Technology Analyst, joins the podcast to unpack some of his predictions on the most impactful forces affec…

1
Navigating Success Unveiling the Best PCD Pharma Franchise Company 2:57

10M ago2:57

2:57

Tune in to our podcast episode as we delve into the pharmaceutical realm, uncovering the industry's top PCD pharma franchise company. Explore the factors that define the best, from product range to support systems. Join the conversation with industry experts as we unravel the secrets to success in the PCD pharma franchise arena. Whether you're an e…

1
Will the Biotech Rebound Run into Pricing Policy Obstacles? 13:25

10M ago13:25

13:25

Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.…

1
Episode: 15 - Facing CMC Challenges in CDMO-Sponsor Relationships for Rare Disease Platforms with Nesredin Mussa 19:42

11M ago19:42

19:42

In this month’s episode of Evaluating Biopharma, host Ben Locwin speaks with Nesredin Mussa, PhD, president of Dynamica Biologics, about navigating the challenges of securing successful CDMO-sponsor relationships for a rare disease manufacturing and testing paradigm, the key contributing factors that may pose within the partnership between the spon…

1
Few IPOs but plenty of follow-on for biotech in 2023 23:35

11M ago23:35

23:35

After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as …

1
U.S. Outlook: Will the US economy achieve a soft landing in 2024? 26:28

12M ago26:28

26:28

As the U.S. economy shows positive signs for growth, inflation, and interest rates in 2024, RBC Capital Markets’ RBC Capital Markets’ Michael Reid, Blake Gwinn, Vito Sperduto and Larry Grafstein analyze the challenges posed by consumer spending, political gridlock, and quantitative tightening. This episode was originally published on RBC's Strategi…

1
Pharma Pioneers: Navigating Excellence with the Best PCD Pharma Company 6:33

1y ago6:33

6:33

Discover the keys to success in the pharmaceutical sector by listening to our podcast, which features the Best PCD Pharma Company. Explore the tactics, ideas, and moral behavior that make these business titans unique. Come have enlightening discussions with influential individuals as we examine the ever-changing Pharma Franchise market and the dedi…

1
Inside the Pharma Franchise World: Navigating Opportunities with Medroots Bio Pharma 5:37

1y ago5:37

5:37

Discover the ever-changing world of pharmaceutical franchise opportunities with us on this insightful podcast episode. Learn about the tactics, difficulties, and accomplishments of Medroots Bio Pharma, a prominent figure in the sector. Discover the nuances of pharmaceutical franchises, the world of healthcare entrepreneurship, and how to succeed in…

1
Raising Venture Capital: A New Playbook for A New Era in Biotech 36:19

1y ago36:19

36:19

In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal stru…

1
Episode: 14 - Strategies and Approaches for Process Intensification With Dr. Stefan Schmidt 16:08

1y ago16:08

16:08

rocess intensification can be an overwhelming experience. In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about strategies and approaches that can help you understand and figure out how to navigate process intensification. Schmidt discusses ways to produce consistent results while using di…

1
ECM: Robust End to Year, Despite Previous Volatility 31:24

1y ago31:24

31:24

As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.RBC Capital Markets による

1
Episode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar Khatwani 19:38

1y ago19:38

19:38

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Santoshkumar Khatwani, Director – Analytical Development, Late-Stage CMC Analytical Team Lead at Sangamo Therapeutics, about impurities in gene therapy processes and the ways to identify them. Khatwani discusses how to determine if these impurities are from the product, the proces…

1
Medroots Bio Pharma Unlocks Opportunities in Healthcare 4:48

1y ago4:48

4:48

Explore the dynamic world of PCD Pharma Franchise in our podcast series. Dive into the pharmaceutical industry's entrepreneurial opportunities, success stories, and expert insights. Discover how to thrive as a PCD franchise partner, the latest healthcare trends, and the path to building a thriving pharmaceutical business. Join us for a dose of indu…

1
Biotech Halftime Report: A Winding Road Ahead 17:26

1y ago17:26

17:26

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. This episode was originally broadcast on Industries in Motion, the RBC podcast.RBC Capital Markets による

1
Episode: 12 - The Risks and Rewards of Speed-to-IND Strategies With Susan Jones 19:32

1+ y ago19:32

19:32

What are some strategies that companies can use to get to IND filing quickly? In this brand new conversation, Evaluating Biopharma podcast host Ben Locwin discusses the risks and rewards of speed-to-IND strategies with Susan Jones, Chief Technology Officer at Tourmaline Bio. Susan delves into her 30 years of experience in the biotech industry, how …

1
The Urgent Need to Address the Youth Mental Health Landscape 28:06

1+ y ago28:06

28:06

U.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.RBC Capital Markets による

1
Episode: 11 - Cell Therapy Strategies: Preparing for Commercial Manufacturing of an Autologous Cell Therapy 21:49

1+ y ago21:49

21:49

In this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufactur…

1
Website Traffic Reveals Biopharma Sales Trends 10:39

1+ y ago10:39

10:39

A new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings.…

1
When to Call it Quits: VCs Making Tough Decisions in a Tough Market 32:02

1+ y ago32:02

32:02

While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies ar…

1
Episode: 10 - Gene Therapy Analytics: How to Make the Right CMC Investments for Your Business 22:43

1+ y ago22:43

22:43

In this episode of Evaluating Biopharma, Mike Kelly, Senior Vice President at Atsena Therapeutics, shares his experiences and provides his advice on how your company can make proper CMC investments to reduce risk and maximize ROI, including: the make or buy decision, ensuring CMC investment to provide regulators what they need, scalability consider…

1
How Biotech M&A is Redefining the Strategic Landscape 25:53

1+ y ago25:53

25:53

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets A…

1
Episode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene Therapy 24:32

1+ y ago24:32

24:32

In this episode of Evaluating Biopharma, Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Susan D'Costa, Chief Technology Officer at Alcyone Therapeutics, who shares her experiences and provides advice on how your company can identify and overcome CMC challenges in gene therapy, including: understanding and mon…

1
Healthcare Should Get Ready for ‘Fast and Furious’ M&A 26:06

1+ y ago26:06

26:06

Hear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deal…

1
Innovation and Growth: Key Ingredients to Healthcare M&A 24:18

1+ y ago24:18

24:18

Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out. This episode features insights from…

1
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? 17:04

1+ y ago17:04

17:04

In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.RBC Capital Markets による

1
Global Blood Therapeutics Commitment to Sickle-Cell Innovation 22:29

1+ y ago22:29

22:29

In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specif…

聞く価値のあるポッドキャスト

ポッドキャスト Biopharma

聞く価値のあるポッドキャスト

クイックリファレンスガイド